Trial Profile

Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 26 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tadalafil (Primary)
Indications Heart failure; Pulmonary hypertension
Focus Therapeutic Use
Acronyms PITCH-HF

Most Recent Events

19 Feb 2014 Status changed from active, no longer recruiting to discontinued according to ClinicalTrials.gov record.
26 Jan 2014 New source identified and integrated (Oregon Health and Science University Institutional Review Board).
01 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com